2012 || Pharmaceuticals || Malignant Mesothelioma – Pipeline Review, H2 2012 || Aarkstore.com

1. Malignant Mesothelioma – Pipeline Review,
H2 2012
Aarkstore.com announces, The Latest market research report is available in
its vast collection:
Malignant Mesothelioma – Pipeline Review, H2 2012
RSS link of Global Markets Direct
Summary
Global Markets Direct’s, Malignant Mesothelioma - Pipeline Review, H2 2012,
provides an overview of the Malignant Mesothelioma therapeutic pipeline. This
report provides information on the therapeutic development for Malignant
Mesothelioma, complete with latest updates, and special features on late-stage and
discontinued projects. It also reviews key players involved in the therapeutic
development for Malignant Mesothelioma. Malignant Mesothelioma - Pipeline
Review, H2 2012 is built using data and information sourced from Global Markets
Direct’s proprietary databases, Company/University websites, SEC filings, investor
presentations and featured press releases from company/university sites and
industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the
availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Malignant Mesothelioma.
- A review of the Malignant Mesothelioma products under development by
companies and universities/research institutes based on information derived from
company and industry-specific sources.
- Coverage of products based on various stages of development ranging from
discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined

2. Malignant Mesothelioma – Pipeline Review,
H2 2012
therapeutics.
Table of contents:
List of Tables 5
List of Figures 6
Introduction 8
Global Markets Direct Report Coverage 8
Malignant Mesothelioma Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Malignant Mesothelioma 10
Malignant Mesothelioma Therapeutics under Development by Companies 12
Malignant Mesothelioma Therapeutics under Investigation by
Universities/Institutes 15
Late Stage Products 19
Comparative Analysis 19
Mid Clinical Stage Products 20
Comparative Analysis 20
Early Clinical Stage Products 21
Comparative Analysis 21
Discovery and Pre-Clinical Stage Products 22
Comparative Analysis 22
Malignant Mesothelioma Therapeutics – Products under Development by
Companies 23
Malignant Mesothelioma Therapeutics – Products under Investigation by
Universities/Institutes 24
Companies Involved in Malignant Mesothelioma Therapeutics Development 30
Viralytics Ltd. 30
Merck & Co., Inc. 31
Oxford BioMedica plc 32
Plexxikon Inc. 33
Pfizer Inc. 34
Aduro BioTech 35
Aeolus Pharmaceuticals, Inc. 36
AEterna Zentaris Inc. 37
Bionomics Limited 38

3. Malignant Mesothelioma – Pipeline Review,
H2 2012
Morphotek, Inc. 39
CanBas Co., Ltd. 40
MolMed S.p.A. 41
Ys Therapeutics Co., Ltd. 42
List of Figures
List of Tables are also include.
For more related Reports Plz follow The link:
Pipeline Review, H2 2012
http://www.aarkstore.com/search/viewresults.asp?search=Pipeline Review, H2
2012&PubId=&pagenum=1
Myocardial Infarction – Pipeline Review, H2 2012
Metastatic Liver Cancer – Pipeline Review, H2 2012
Mantle Cell Lymphoma – Pipeline Review, H2 2012
Malignant Mesothelioma – Pipeline Review, H2 2012
Rectal Cancer – Pipeline Review, H2 2012
Chemotherapy Effects – Pipeline Review, H2 2012
Follicular Lymphoma – Pipeline Review, H2 2012

4. Malignant Mesothelioma – Pipeline Review,
H2 2012
Sleep Disorders – Pipeline Review, H2 2012
Neuroblastoma – Pipeline Review, H2 2012
Cytomegalovirus (HHV-5) Infections – Pipeline Review, H2 2012
Search More Reports Related to This Category :
Pharmaceuticals and Healthcare
http://www.aarkstore.com/search/viewresults.asp?search=Pharmaceuticals and
Healthcare&PubId=&pagenum=1
For More details Plz do contact :
Aarkstore Enterprise
Lavanya
Phone:08149852585
Email: enquiry@aarkstore.com